PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 1,378 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels sold 1,378 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $69,037.80. Following the transaction, the chief executive officer now owns 85,427 shares in the company, valued at approximately $4,279,892.70. The trade was a 1.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Pauwels also recently made the following trade(s):

• On Tuesday, January 7th, Eric Pauwels sold 1,599 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $72,498.66.

PTC Therapeutics Stock Up 0.6 %

PTCT stock opened at $50.69 on Friday. The company has a fifty day moving average price of $46.67 and a 200-day moving average price of $41.49. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $54.16.

Hedge Funds Weigh In On PTC Therapeutics

Several large investors have recently modified their holdings of PTCT. CWM LLC raised its stake in shares of PTC Therapeutics by 354.7% during the third quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 2,096 shares during the last quarter. Creative Planning raised its stake in shares of PTC Therapeutics by 8.1% during the third quarter. Creative Planning now owns 10,944 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 816 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of PTC Therapeutics by 32.1% during the third quarter. Assenagon Asset Management S.A. now owns 492,464 shares of the biopharmaceutical company’s stock valued at $18,270,000 after acquiring an additional 119,637 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in PTC Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 492 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in PTC Therapeutics by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,795 shares of the biopharmaceutical company’s stock worth $549,000 after buying an additional 5,783 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on PTCT shares. Royal Bank of Canada increased their target price on shares of PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a research report on Tuesday. Morgan Stanley upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $45.00 to $67.00 in a research report on Friday, December 13th. UBS Group increased their price target on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald increased their price target on shares of PTC Therapeutics from $76.00 to $113.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, The Goldman Sachs Group increased their price target on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a research report on Wednesday, December 4th. Three analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and an average price target of $58.85.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.